• Publications
  • Influence
Medical Treatment in Elderly Patients with Non-Small Cell Lung Cancer
Opinion statementLung cancer is the leading cause of cancer-related deaths worldwide. In the USA, ≈60 % of lung cancer cases are diagnosed in elderly patients (≥65 years of age). However, elderlyExpand
  • 6
  • 1
Update of systemic immunotherapy for advanced urothelial carcinoma.
PURPOSE Until recently, therapeutic options for metastatic urothelial carcinoma (UC) were limited to cytotoxic chemotherapy. Cisplatin-based combination chemotherapy has proven benefit in theExpand
  • 6
The Evolving Role of Biomarkers in Personalized Lung Cancer Therapy
Prior to the last decade, treatment for lung cancer was differentiated only by the main histological groups of small cell lung cancer (SCLC) and NSCLC. However, it is now known that differences inExpand
  • 6
Emerging treatment for ALK-positive lung cancer
ABSTRACT Introduction: Lung cancer is associated with poor prognosis and limited benefit from chemotherapy. The treatment of non-small cell lung cancer (NSCLC) has been revolutionized by theExpand
  • 2
Distinguishing head and neck cancer metastasis from second primary squamous lung cancer in the genomic era.
e17506Background: Patients with head and neck squamous cell carcinoma (HNSCC) are at risk for both lung metastases and secondary primary cancers of the lung. Given the histopathologic similarityExpand
  • 1
New & Emerging Drugs for Squamous Cell Lung Cancer
Lung Cancer is the leading cause of cancer-related death worldwide. Squamous cell lung cancer (SQCLC) is the second most common histology (20-30% of cases) among non-small cell lung cancers (NSCLC),Expand
  • 3
Survival Disparities in Black Patients With EGFR-mutated Non-small-cell Lung Cancer.
BACKGROUND Little is known about the difference between black and non-black patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC), particularly regardingExpand
Unusual pattern of KRAS mutations in inner city patients with NSCLC.
e20033Background: KRAS mutations (mut) occur in 15-25% of non-squamous NSCLC and may be associated with poor survival and primary EGFR TKI resistance. Distinct subgroups of KRAS-mut non-squamousExpand
Synchronous Bone Metastasis From Multiple Myeloma and Prostate Adenocarcinoma as Initial Presentation of Coexistent Malignancies
The radiographic appearance of bone metastases is usually determined by tumor histology and can be osteolytic, osteoblastic, or mixed. We present a patient with coexistent bone metastasis fromExpand